Loading...
PRDS logo

Pardes Biosciences, Inc.NasdaqGM:PRDS Stock Report

Market Cap US$131.2m
Share Price
n/a
1Y-40.0%
7D0.5%
1D0%
Portfolio Value
​
View

Pardes Biosciences, Inc.

NasdaqGM:PRDS Stock Report

Market Cap: US$131.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Pardes Biosciences (PRDS) Stock Overview

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. More details

PRDS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


PRDS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW441,026 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
441,026 investors already sharing narratives
View all narratives

Pardes Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pardes Biosciences
Historical stock prices
Current Share PriceUS$2.16
52 Week HighUS$3.67
52 Week LowUS$0.75
Beta0.42
1 Month Change2.37%
3 Month Change14.29%
1 Year Change-40.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-79.98%

Recent News & Updates

Analysis Article • Jul 18

We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 20

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent updates

Analysis Article • Jul 18

We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 20

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 01

We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 13

Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19

Pardes Biosciences (NASDAQ:PRDS) said it began a phase 2 trial of oral drug PBI-0451 to treat non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness. The company expects to enroll 210 patients in the study at ~75 sites in the U.S. to evaluate antiviral activity, safety, and efficacy of PBI-0451, compared to placebo. The main goal will be to determine the proportion of patients below the detection limit (in nasal swab samples) for infectious SARS-CoV-2, on day three, the company said in a Sept. 13 press release. "PBI-0451 has the potential to be a stand-alone SARS-CoV-2 protease inhibitor that can be easily prescribed and administered to alleviate the burden of COVID-19 to patients and healthcare systems," said Pardes Chair and CEO Tom Wiggans. The company expects interim data from the study in Q1 2023.
Seeking Alpha • Aug 15

Pardes Biosciences GAAP EPS of -$0.48

Pardes Biosciences press release (NASDAQ:PRDS): Q2 GAAP EPS of -$0.48. Pardes’ cash and cash equivalents as of June 30, 2022, were $228.6M compared to $247.9M as of March 31, 2022. The company expects that the cash and cash equivalents it had on hand as of June 30, 2022, will be sufficient to fund operating expenses and capital expenditures into the second half of 2023.
Analysis Article • Jun 14

Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 21

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

Pardes Biosciences is developing a novel coronavirus protease inhibitor platform that is extendable to other variants and viruses. The company’s lead candidate demonstrated selective activity against multiple coronaviruses, including SARS-CoV-2 and its variants, and other viruses like SARS, MERS, and even related to common cold. The company recently consummated a business combination and began trading on NASDAQ from 12/27/2021.

Shareholder Returns

PRDSUS BiotechsUS Market
7D0.5%-5.2%-0.9%
1Y-40.0%37.6%14.2%

Return vs Industry: PRDS underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: PRDS underperformed the US Market which returned 11.7% over the past year.

Price Volatility

Is PRDS's price volatile compared to industry and market?
PRDS volatility
PRDS Average Weekly Movement5.0%
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: PRDS has not had significant price volatility in the past 3 months.

Volatility Over Time: PRDS's weekly volatility has decreased from 12% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
202057Tom Wigganswww.pardesbio.com

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Pardes Biosciences, Inc. Fundamentals Summary

How do Pardes Biosciences's earnings and revenue compare to its market cap?
PRDS fundamental statistics
Market capUS$131.19m
Earnings (TTM)-US$76.14m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.7x
P/E Ratio

Is PRDS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRDS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$76.14m
Earnings-US$76.14m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.25
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PRDS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/01 10:09
End of Day Share Price 2023/08/30 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pardes Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas BuchananCitizens JMP Securities, LLC
Yuchen DingJefferies LLC
Roanna Clarissa RuizLeerink Partners LLC